欧林生物(688319) - 2025 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2025 reached RMB 704.16 million, a year-on-year increase of 19.58%[4] - Operating profit increased to RMB 30.86 million, reflecting a growth of 44.80% compared to the previous year[4] - Total profit rose to RMB 31.89 million, marking a 43.00% increase year-on-year[4] - Net profit attributable to shareholders of the parent company was RMB 22.23 million, up 7.10% from the previous year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased to RMB 9.88 million, a decline of 11.64%[4] - Basic earnings per share increased to RMB 0.0548, representing a growth of 7.03%[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 2,019.99 million, an increase of 11.78% from the beginning of the period[4] - Shareholders' equity attributable to the parent company decreased to RMB 903.68 million, down 2.27% from the beginning of the period[4] Market and Sales - The company strengthened market promotion, leading to stable growth in sales of tetanus vaccines[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the 2025 annual report[7]